Lower dose of new pulmonary fibrosis drug shows promising results
Bristol Myers Squibb announced trial results showing a lower dose of admilparant successfully slowed pulmonary fibrosis progression.
Bristol Myers Squibb announced trial results showing a lower dose of admilparant successfully slowed pulmonary fibrosis progression.